Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 67877-642

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 67877-642). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lurasidone-structure (Lurasidone 1)

Chemical structure of lurasidone hydrochloride, showing its molecular framework including rings and functional groups.*

FDA Label Image

Lurasidone-120mg-500tab-1 (Lurasidone 120mg 500tab 1)

Label for Lurasidone Hydrochloride Tablets 120 mg, film-coated oral tablets. The label indicates a quantity of 500 tablets, manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ. It includes storage instructions and a barcode, with a caution to dispense the accompanying medication guide.*

FDA Label Image

Lurasidone-20mg-30tab-1 (Lurasidone 20mg 30tab 1)

Label for Lurasidone Hydrochloride Tablets 20 mg, film-coated oral tablets. The label states the active ingredient strength, storage instructions, manufacturer as Alkem Laboratories Ltd., India, and distributor as Ascend Laboratories, LLC, Parsippany, NJ. The package contains 30 tablets and is marked Rx Only. Additional text advises to see package insert for dosage and use, and includes a warning to dispense with the accompanying Medication Guide.*

FDA Label Image

Lurasidone-40mg-90tab-1 (Lurasidone 40mg 90tab 1)

Label for Lurasidone Hydrochloride Tablets 40 mg, film-coated oral tablets. The label indicates a package containing 90 tablets, distributed by Ascend Laboratories, LLC, and manufactured by Alkem Laboratories Ltd., India. It includes storage instructions, a warning to give the medication guide with each dispensation, and a barcode.*

FDA Label Image

Lurasidone-60mg-30tab-1 (Lurasidone 60mg 30tab 1)

Label for Lurasidone Hydrochloride Tablets 60 mg film-coated tablets by Ascend Laboratories, LLC. The label includes dosage information, storage instructions, manufacturer details (Alkem Laboratories Ltd., India), and a barcode. The package contains 30 tablets and is marked Rx Only.*

FDA Label Image

Lurasidone-80mg-100tab-cart-1 (Lurasidone 80mg 100tab Cart 1)

Packaging label for Lurasidone Hydrochloride Tablets 80 mg per tablet, film-coated, oral dosage form. The label indicates a package size of 100 tablets (10 cards with 10 tablets each) and is labeled for prescription use only (Rx Only). Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ. Storage and dispensing instructions are also included on the label.*

FDA Label Image

Lurasidone-fig2 (Lurasidone Fig2)

A scatter plot chart titled 'Impact of other drugs on Lurasidone Pharmacokinetics (PK).' It shows fold changes and 90% confidence intervals (CI) for Cmax and AUC pharmacokinetic parameters of lurasidone when co-administered with various drugs, including strong CYP3A4 inhibitor ketoconazole, moderate CYP3A4 inhibitor diltiazem, strong CYP3A4 inducer rifampin, and lithium. The x-axis represents change relative to lurasidone alone, ranging from -4 to 4.*

FDA Label Image

Lurasidone-fig2 (Lurasidone Fig3)

A pharmacokinetic chart depicting fold changes and 90% confidence intervals for various interacting drugs when taken with another drug. The chart lists digoxin, midazolam, ethinyl estradiol, norelgestromin, and lithium, showing their effects on parameters such as Cmax, AUC, and trough levels, with changes relative to the interacting drug alone.*

FDA Label Image

Lurasidone-fig3 (Lurasidone Fig4)

A forest plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC in populations with renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population subgroups by gender and race (female, Asian), compared to reference values. The x-axis represents change relative to reference, ranging from 0 to 6.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.